Every material Form 8-K Elevance Health filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Elevance Health reported third-quarter 2026 operating revenue of $50.4 billion, up 0.7% from a year earlier, and diluted earnings per share of $6.27, up 17.9% from $5.32, which included a net non-operating benefit of $1.85 per share. The company raised its full-year 2026 diluted EPS guidance to at least $22.00 and adjusted diluted EPS guidance to at least $29.00, though the Health Benefits operating gain fell 27.5%. For shareholders, the higher outlook is the main change, while nine-month diluted EPS of $21.01 was down 7.3% from the prior year.
Third-quarter operating revenue was $50.4 billion, up 0.7% from $50.1 billion a year earlier.
Diluted EPS was $6.27 versus $5.32 a year earlier; adjusted diluted EPS was $6.99 versus $6.03.
Full-year 2026 diluted EPS guidance was raised to at least $22.00; adjusted diluted EPS guidance was raised to at least $29.00.
Health Benefits operating gain fell 27.5% to $0.4 billion, and a $1.72 quarterly dividend was declared for payment on December 18, 2026.
Elevance Health reported second-quarter 2026 operating revenue of $49.8 billion, up 0.8% from a year earlier, while diluted earnings per share fell 13.1% to $6.71 from $7.72. The company raised its full-year 2026 diluted EPS guidance to at least $20.10 and its adjusted EPS guidance to at least $27.00, and said it is accelerating targeted investments. For shareholders, the higher outlook comes alongside lower quarterly profit and a higher benefit expense ratio.
Operating revenue was $49.8 billion in the second quarter of 2026, up from $49.4 billion a year earlier.
Diluted EPS was $6.71 versus $7.72 a year earlier; adjusted diluted EPS was $7.45 versus $8.84.
Full-year 2026 diluted EPS guidance was raised to at least $20.10 and adjusted diluted EPS guidance to at least $27.00.
Full-year 2026 operating cash flow guidance was raised to at least $6.0 billion; a $1.72 quarterly dividend is payable September 25, 2026.
Elevance Health reported first quarter 2026 operating revenue of $49.5 billion, up 1.5% from a year earlier, while GAAP diluted EPS fell to $8.00 from $9.61 after a $935 million accrual related to a CMS notice. Adjusted diluted EPS rose 5.1% to $12.58, and the company raised its full-year 2026 adjusted EPS guidance to at least $26.75, though GAAP diluted EPS guidance is at least $19.85 including the CMS estimate.
Operating revenue was $49.5 billion, up 1.5% from the prior year quarter, driven by higher premium yields and CarelonRx product revenue.
Diluted EPS was $8.00 versus $9.61 a year earlier; adjusted diluted EPS was $12.58 versus $11.97.
The $935 million accrual reflects the company's current best estimate of potential exposure tied to a CMS notice dated February 27, 2026.
Full-year 2026 adjusted diluted EPS guidance was raised to at least $26.75; the company returned $1.5 billion to shareholders in the quarter and declared a $1.72 per share dividend payable June 25, 2026.
Elevance Health announced management changes: CFO Mark Kaye will add oversight of Carelon, and Felicia Norwood will lead a consolidated Health Benefits organization. Carelon president Peter D. Haytaian leaves that role effective May 4, 2026, and will serve as Special Advisor through December 31, 2026. The company also reaffirmed its 2026 earnings and benefit expense ratio guidance, so the leadership changes come without a change to its outlook.
Peter D. Haytaian leaves his role as President of Carelon effective May 4, 2026, to devote more time to family commitments; he will serve as Special Advisor through December 31, 2026.
CFO Mark Kaye expands his responsibilities to include oversight of Carelon; Felicia Norwood assumes responsibility for the consolidated Health Benefits organization.
2026 guidance reaffirmed: shareholders' earnings of at least $22.30 per diluted share, including about $3.20 per diluted share of net unfavorable items; adjusted earnings of at least $25.50 per diluted share.
Benefit expense ratio guidance for 2026 reaffirmed at 90.2% plus or minus 50 basis points.
Elevance Health reported fourth quarter 2025 operating revenue of $49.3 billion, up 10% from a year earlier, and GAAP diluted EPS of $2.47 versus $1.81. For the full year, GAAP diluted EPS fell 1.8% to $25.21 and adjusted diluted EPS fell 8.3% to $30.29. The company projects 2026 adjusted diluted EPS of at least $25.50 and GAAP diluted EPS of at least $22.30, both below 2025 levels.
Q4 2025 operating gain was $0.3 billion versus $0.7 billion a year earlier; benefit expense ratio rose to 93.5%, up 110 basis points.
Full-year 2025 adjusted operating gain was $7.5 billion versus $9.3 billion in 2024.
2026 outlook: total operating revenue expected to decline at a low single digit rate; adjusted operating gain of at least $6.8 billion.
Returned $4.1 billion to shareholders in 2025; Q1 2026 dividend declared at $1.72 per share, payable March 25, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Elevance Health filing is on SEC EDGAR ↗. 8-K briefs of other companies →